

Mina Tadrous

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8096396/mina-tadrous-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

1,876
citations

20
h-index

40
g-index

173
ext. papers

2,800
ext. citations

4
avg, IF

5.5
L-index

#	Paper	IF	Citations
151	Understanding Engagement and the Potential Impact of an Electronic Drug Repository: Multi-Methods Study.. <i>JMIR Formative Research</i> , 2022 , 6, e27158	2.5	
150	Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19).. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	3
149	Real-world cost-effectiveness of first-line gemcitabine + nab-paclitaxel versus FOLFIRINOX in patients with advanced pancreatic cancer: A population-based retrospective cohort study in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 529-529	2.2	1
148	Effect of the COVID-19 pandemic on adversity in individuals receiving anticoagulation for atrial fibrillation: A nationally representative administrative health claims analysis.. <i>American Heart Journal Plus</i> , 2022 , 13, 100096		0
147	Audit and feedback in community pharmacy: An untapped strategy of quality improvement.. <i>Canadian Pharmacists Journal</i> , 2022 , 155, 79-81	1.3	
146	Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study.. <i>CMAJ Open</i> , 2022 , 10, E262-E268	2.5	
145	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.. <i>Current Oncology</i> , 2022 , 29, 2046-2063	2.8	
144	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 846-855	27.4	4
143	Trends in Canadian prescription drug purchasing: 2001-2020.. <i>Journal of Pharmaceutical Policy and Practice</i> , 2022 , 15, 20	3.2	0
142	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors.. <i>Canadian Journal of Hospital Pharmacy</i> , 2022 , 75, 104-107	0.5	0
141	National trends in prescription drug expenditures and projections for 2022.. <i>American Journal of Health-System Pharmacy</i> , 2022 ,	2.2	1
140	Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.. <i>International Journal of Drug Policy</i> , 2022 , 103, 103644	5.5	4
139	Hospital pharmacist discharge care is independently associated with reduced risk of readmissions for patients with chronic obstructive pulmonary disease: A propensity-matched cohort study.. <i>Canadian Pharmacists Journal</i> , 2022 , 155, 101-106	1.3	
138	Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study.. <i>Canada Communicable Disease Report</i> , 2022 , 48, 179-180	3.1	
137	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data.. <i>Cmaj</i> , 2022 , 194, E556-E560	3.5	1
136	Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.. <i>Drug and Alcohol Dependence</i> , 2022 , 236, 109459	4.9	1
135	Virtual care use during the COVID-19 pandemic and its impact on healthcare utilization in patients with chronic disease: A population-based repeated cross-sectional study.. <i>PLoS ONE</i> , 2022 , 17, e0267218	3.7	3

134	Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study.. <i>Drug and Alcohol Dependence</i> , 2022 , 236, 109473	4.9	0
133	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis.. <i>CMAJ Open</i> , 2021 , 9, E1181-E1186	2.5	0
132	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. <i>CMAJ Open</i> , 2021 , 9, E1055-E1062	2.5	2
131	Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. <i>CMAJ Open</i> , 2021 , 9, E1128-E1133	2.5	0
130	Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1504-1515	27.4	9
129	Where to begin? Thirty must-read papers for newcomers to pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6	0
128	Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. <i>CMAJ Open</i> , 2021 , 9, E1048-E1054	2.5	
127	Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.. <i>Current Oncology</i> , 2021 , 28, 4645-4654	2.8	2
126	The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. <i>Depression and Anxiety</i> , 2021 ,	8.4	2
125	Mapping global trends in vaccine sales before and during the first wave of the COVID-19 pandemic: a cross-sectional time-series analysis. <i>BMJ Global Health</i> , 2021 , 6,	6.6	2
124	Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. <i>Current Oncology</i> , 2021 , 28, 4174-4183	2.8	3
123	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. <i>JAMA Network Open</i> , 2021 , 4, e2130795	10.4	3
122	Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 581-583	4	1
121	Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 671-684	2.6	13
120	Effects of a single-entry intake system on access to outpatient visits to specialist physicians and allied health professionals: a systematic review. <i>CMAJ Open</i> , 2021 , 9, E413-E423	2.5	2
119	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 444-452	1.9	
118	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1738-1740	0.7	2
117	Rural Telemedicine Use Before and During the COVID-19 Pandemic: Repeated Cross-sectional Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e26960	7.6	22

116	National trends in prescription drug expenditures and projections for 2021. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 1294-1308	2.2	14
115	Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis. <i>JAMA Dermatology</i> , 2021 , 157, 549-558	5.1	12
114	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. <i>American Journal of Preventive Medicine</i> , 2021 , 60, 831-839	6.1	2
113	Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. <i>Viruses</i> , 2021 , 13,	6.2	5
112	Measuring the impacts of the Using Antibiotics Wisely campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2472-2478	5.1	2
111	Old dog with new tricks: An introduction to real-world evidence for pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 2277-2280	2.2	1
110	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. <i>Clinical Infectious Diseases</i> , 2021 , 72, 279-284	11.6	3
109	Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis. <i>Addiction</i> , 2021 , 116, 1514-1520	4.6	3
108	Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 379-389	2.6	2
107	The missed opportunity for real-world evidence to shape our understanding of medical cannabis. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 732-734	3.8	1
106	Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 739-745	6.1	7
105	Atopic dermatitis and bone health: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 615-628	4.6	3
104	'Fitting in the pharmacist' - a qualitative analysis of the perceived relationship between community pharmacists and older adults with complex care needs. <i>International Journal of Pharmacy Practice</i> , 2021 , 29, 428-434	1.7	0
103	A qualitative study of a publicly funded pharmacy-dispensed naloxone program. <i>International Journal of Drug Policy</i> , 2021 , 92, 103146	5.5	7
102	Choppy waters: The importance of accounting for shifting drug utilization during the COVID-19 pandemic in future observational drug-related studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 128, 649-651	3.1	1
101	Safety of Systemic Medications Among Older Adults With Psoriasis and Atopic Dermatitis: A Systematic Review of Observational Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021 , 25, 397-408	1.6	0
100	Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada. <i>Canadian Liver Journal</i> , 2021 , 4, 51-58	0.3	2
99	Sum of the parts: Ensuring a resilient global drug supply chain. <i>Infection Control and Hospital Epidemiology</i> , 2021 , 42, 598-599	2	2

98	Changes in Purchases for Intensive Care Medicines During the COVID-19 Pandemic: A Global Time Series Study. <i>Chest</i> , 2021 , 160, 2123-2134	5.3	1
97	Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. <i>JAMA Network Open</i> , 2021 , 4, e2118441	10.4	9
96	Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. <i>BMJ, The</i> , 2021 , 374, n1943	5.9	79
95	Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. <i>Frontiers in Pharmacology</i> , 2021 , 12, 709349	5.6	0
94	Background rates of all-cause mortality, hospitalizations, and emergency department visits among nursing home residents in Ontario, Canada to inform COVID-19 vaccine safety assessments. <i>Vaccine</i> , 2021 , 39, 5265-5270	4.1	1
93	Opioid Prescribing in United States Health Systems, 2015 to 2019. <i>Value in Health</i> , 2021 , 24, 1279-1284	3.3	1
92	Using Administrative Data to Explore Potentially Aberrant Provision of Virtual Care During COVID-19: Retrospective Cohort Study of Ontario Provincial Data. <i>Journal of Medical Internet Research</i> , 2021 , 23, e29396	7.6	1
91	Virtual care use before and during the COVID-19 pandemic: a repeated cross-sectional study. <i>CMAJ Open</i> , 2021 , 9, E107-E114	2.5	42
90	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 444-452	1.9	1
89	Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. <i>Drug and Alcohol Dependence</i> , 2020 , 216, 108238	4.9	6
88	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 864-872	2.6	5
87	Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes: A Cluster Randomized Clinical Trial. <i>JAMA Network Open</i> , 2020 , 3, e205724	10.4	4
86	Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. <i>BMJ Open</i> , 2020 , 10, e032884	3	18
85	Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle. <i>Healthcare Policy</i> , 2020 , 15, 41-47	1.1	1
84	Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis. <i>Europace</i> , 2020 , 22, 854-869	3.9	5
83	Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. <i>CMAJ Open</i> , 2020 , 8, E297-E303	2.5	3
82	Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 36, 12-19	1.8	2
81	Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. <i>Journal of the American Dental Association</i> , 2020 , 151, 43-50	1.9	2

80	Topical corticosteroids and type 2 diabetes mellitus: a critical appraisal. <i>British Journal of Dermatology</i> , 2020 , 183, 37-38	4	
79	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. <i>Value in Health</i> , 2020 , 23, 1137-1141	3.3	7
78	National trends in prescription drug expenditures and projections for 2020. <i>American Journal of Health-System Pharmacy</i> , 2020 , 77, 1213-1230	2.2	17
77	Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis: A Systematic Review. <i>JAMA Dermatology</i> , 2020 , 156, 1240-1245	5.1	9
76	Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department: A Systematic Review and Network Meta-analysis. <i>Annals of Emergency Medicine</i> , 2020 , 76, 14-30	2.1	6
75	Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. <i>CMAJ Open</i> , 2019 , 7, E582-E589	2.5	7
74	"Like being put on an ice floe and shoved away": A qualitative study of the impacts of opioid-related policy changes on people who take opioids. <i>International Journal of Drug Policy</i> , 2019 , 66, 15-22	5.5	36
73	National trends in prescription drug expenditures and projections for 2019. <i>American Journal of Health-System Pharmacy</i> , 2019 , 76, 1105-1121	2.2	20
72	Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer's Dementia. <i>PLoS ONE</i> , 2019 , 14, e0215223	3.7	0
71	Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 726-733	2.6	10
70	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. <i>International Journal of Drug Policy</i> , 2019 , 66, 82-86	5.5	5
69	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. <i>Canadian Journal of Diabetes</i> , 2019 , 43, 179-185.e1	2.1	7
68	Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2019 , 8, 207	3	17
67	Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study. <i>JAMA Internal Medicine</i> , 2019 , 179, 1436-1439	11.5	3
66	The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. <i>PLoS ONE</i> , 2019 , 14, e0223589	3.7	16
65	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. <i>JAMA Network Open</i> , 2019 , 2, e1913304	10.4	9
64	Quality of primary care among individuals receiving treatment for opioid use disorder. <i>Canadian Family Physician</i> , 2019 , 65, 343-351	0.9	8
63	Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. <i>BMJ Open</i> , 2019 , 9, e028125	3	3

62	WHAT'S OLD IS NEW: USING ARTIFICIAL INTELLIGENCE TO ACCELERATE DISCOVERY OF NEW TREATMENTS. <i>Innovation in Aging</i> , 2019 , 3, S16-S17	0.1	78
61	Further Evidence to Monitor Long-term Proton Pump Inhibitor Use. <i>JAMA Network Open</i> , 2019 , 2, e1916184	1.4	3
60	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. <i>Neurourology and Urodynamics</i> , 2018 , 37, 1693-1700	2.3	2
59	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. <i>CMAJ Open</i> , 2018 , 6, E132-E138	2.5	4
58	Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. <i>Canadian Journal of Psychiatry</i> , 2018 , 63, 361-369	4.8	36
57	A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. <i>BMC Musculoskeletal Disorders</i> , 2018 , 19, 160	2.8	4
56	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 464-468	1.9	1
55	Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. <i>Drug and Alcohol Dependence</i> , 2018 , 191, 86-90	4.9	16
54	Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. <i>CMAJ Open</i> , 2018 , 6, E110-E117	2.5	8
53	Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. <i>Respiratory Medicine</i> , 2018 , 143, 1-7	4.6	1
52	Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. <i>PLoS Medicine</i> , 2018 , 15, e1002584	11.6	51
51	Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study. <i>Canadian Urological Association Journal</i> , 2018 , 12, E142-E145	1.2	4
50	Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario. <i>Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice</i> , 2018 , 38, 256-262	2.2	8
49	Évaluation des premiers effets du retrait des opioïdes à forte concentration sur les schémas de prescription en Ontario. <i>Promotion De La Santé Et Prévention Des Maladies Chroniques Au Canada</i> , 2018 , 38, 291-298	0	0
48	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018 , 120, 59-65.e2	3.2	13
47	Measuring the Burden of Opioid-related Mortality in Ontario, Canada. <i>Journal of Addiction Medicine</i> , 2018 , 12, 418-419	3.8	31
46	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. <i>Canadian Geriatrics Journal</i> , 2018 , 21, 269-273	2.8	9
45	Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. <i>BMJ, The</i> , 2018 , 362, k3207	5.9	65

44	Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. <i>Pain</i> , 2018 , 159, 1562-1568	8	35
43	Network meta-analysis: an introduction for pharmacists. <i>International Journal of Clinical Pharmacy</i> , 2018 , 40, 942-947	2.3	5
42	The Burden of Opioid-Related Mortality in the United States. <i>JAMA Network Open</i> , 2018 , 1, e180217	10.4	345
41	History and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over time. <i>BMJ Open</i> , 2018 , 8, e019110	3	1
40	Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice. <i>Journal of Clinical Epidemiology</i> , 2017 , 84, 150-160	5.7	9
39	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. <i>Cmaj</i> , 2017 , 189, E4-E10	3.5	34
38	Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. <i>Pain Medicine</i> , 2017 , 18, 1019-1026	2.8	14
37	Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. <i>Drug and Alcohol Dependence</i> , 2017 , 177, 315-321	4.9	13
36	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes: A Population-Based Study. <i>JAMA Internal Medicine</i> , 2017 , 177, 61-66	11.5	10
35	The appropriateness and persistence of testosterone replacement therapy in Ontario. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 119-126	2.6	7
34	Latest trends in opioid-related deaths in Ontario 2017 ,		26
33	Behind the prescriptions: a snapshot of opioid use across all Ontarians 2017 ,		9
32	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017 , 13, 68-78	1.1	2
31	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 803-807 ²	2.2	2
30	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. <i>Drugs - Real World Outcomes</i> , 2016 , 3, 175-182	2.2	7
29	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. <i>Canadian Journal of Diabetes</i> , 2016 , 40, 431-435	2.1	9
28	Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. <i>Canadian Journal of Psychiatry</i> , 2016 , 61, 758-765	4.8	16
27	Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. <i>Osteoporosis International</i> , 2016 , 27, 1989-98	5.3	32

26	Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. <i>Osteoporosis International</i> , 2016 , 27, 1709-18	5.3	71
25	Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. <i>Implementation Science</i> , 2016 , 11, 45	8.4	15
24	Varenicline and Risk of Self-Harm: A Nested Case-Control Study. <i>PLoS ONE</i> , 2016 , 11, e0163681	3.7	1
23	Off-label use of inhaled tobramycin in Ontario, Canada. <i>Thorax</i> , 2016 , 71, 862-4	7.3	0
22	Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. <i>Osteoporosis International</i> , 2015 , 26, 1525-33	5.3	12
21	Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study. <i>CMAJ Open</i> , 2015 , 3, E91-6	2.5	6
20	Performance of the disease risk score in a cohort study with policy-induced selection bias. <i>Journal of Comparative Effectiveness Research</i> , 2015 , 4, 607-14	2.1	
19	Initial uptake of the Ontario Pharmacy Smoking Cessation Program: Descriptive analysis over 2 years. <i>Canadian Pharmacists Journal</i> , 2015 , 148, 29-40	1.3	14
18	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. <i>Osteoporosis International</i> , 2014 , 25, 1225-35	5.3	26
17	Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen. <i>Osteoporosis International</i> , 2014 , 25, 2671-2	5.3	8
16	Proceed with caution: The possible impact of preferred-provider networks. <i>Canadian Pharmacists Journal</i> , 2014 , 147, 273-4	1.3	
15	Variation in the days supply field for osteoporosis medications in Ontario. <i>Archives of Osteoporosis</i> , 2013 , 8, 128	2.9	8
14	Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study. <i>CMAJ Open</i> , 2013 , 1, E97-E105	2.5	6
13	Disease risk score as a confounder summary method: systematic review and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 122-9	2.6	33
12	Does depression lead to influenza? - A systematic literature analysis. <i>Journal of Affective Disorders</i> , 2012 , 138, 41-5	6.6	3
11	Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012 , 12, 699-709	2.2	6
10	Establishing a Complete Drug Information Triad: Academic, Industry, and Hospital Training. <i>Drug Information Journal</i> , 2011 , 45, 641-644		1
9	Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 7-18	4	53

8	Thimerosal-containing vaccines and autism: a review of recent epidemiologic studies. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2010 , 15, 173-81	1.6	10
7	First renin inhibitor, aliskiren, for the treatment of hypertension. <i>International Journal of Clinical Pharmacy</i> , 2008 , 30, 741-9		5
6	Comparison of admission rates to a non-traditional Doctor of Pharmacy programme using internet-based multiple-mini interviews versus on-site. <i>Pharmacy Education</i> , 282-286		1
5	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design study		9
4	Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario		77
3	Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. <i>Canadian Liver Journal</i> , e20200041	0.3	1
2	Beliefs associated with Intentions of Non-Physician Healthcare Workers to Receive the COVID-19 Vaccine in Ontario, Canada		4
1	Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines Against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario, Canada. <i>SSRN Electronic Journal</i> ,	1	5